บทความทั้งหมด

Does adding bortezomib to standard treatment improve late antibody-mediated rejection? — Multicenter randomized trial summary

A French multicenter randomized trial comparing standard therapy ± bortezomib showed no significant efficacy difference, but the combination group had more serious adverse events.[1]